Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel

Vaccine

Volumn 32, Issue 30, 2014, Pages 3805-3809

  Patel, Manisha ^a   Romero Steiner, Sandra ^a,b   Broderick, Michael P ^c   Thomas, Cynthia G ^a   Plikaytis, Brian D ^a   Schmidt, Daniel S ^a   Johnson, Scott E ^a   Milton, Andrea S ^a   Carlone, George M ^a   Clark, Thomas A ^a   Messonnier, Nancy E ^a   Cohn, Amanda C ^a   Faix, Dennis J ^c  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Antibody persistence; Conjugate; Meningococcal vaccine; Polysaccharide

Indexed keywords

MENINGOCOCCAL POLYSACCHARIDE VACCINE; MENINGOCOCCUS VACCINE; QUADRIVALENT MENINGOCOCCAL VACCINE CONJUGATED TO DIPHTHERIA TOXOID; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; SEROLOGY; SOLDIER; UNITED STATES; VACCINATION; ANTIBODY PRODUCTION; BLOOD; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; RETROSPECTIVE STUDY; SERUM BACTERICIDAL ANTIBODY ASSAY; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MILITARY PERSONNEL; NEISSERIA MENINGITIDIS, SEROGROUP C; RETROSPECTIVE STUDIES; SERUM BACTERICIDAL ANTIBODY ASSAY; TIME FACTORS; UNITED STATES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84922241820     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.001     Document Type: Article

References (24)

1. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50(January (2)):184-191.
2. Erickson L., De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998, 26(May (5)):1159-1164.
3. Wang J.F., Caugant D.A., Morelli G., Koumare B., Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 1993, 167(June (6)):1320-1329.
4. Macneil J.R., Thomas J.D., Cohn A.C. Meningococcal disease: shifting epidemiology and genetic mechanisms that may contribute to serogroup C virulence. Curr Infect Dis Rep 2011, 13(August (4)):374-379.
5. Artenstein M.S., Schneider H., Tingley M.D. Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964-70. Bull World Health Organ 1971, 45(3):275-278.
6. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2005, 54(May (RR-7)):1-21.
7. Gill C.J., Baxter R., Anemona A., Ciavarro G., Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents. Hum Vaccin 2010, 6(November (11)):881-887.
8. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel M.J., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005, 159(October (10)):907-913.
9. Broderick M.P., Faix D.J., Hansen C.J., Blair P.J. Trends in meningococcal disease in the United States military, 1971-2010. Emerg Infect Dis 2012, 18(September (9)):1430-1437.
10. Rubertone M.V., Brundage J.F. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 2002, 92(December (12)):1900-1904.
11. Armed Forces Health Surveillance Center, Fiscal Year 2011 Report 2011, Available from: http://www.afhsc.mil/viewDocument?file=AFHSC_AnnualReport_WEB.pdf.
12. Borrow R., Carlone G.M., Serogroup B. C serum bactericidal assays. Methods Mol Med 2001, 66:289-304.
13. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997, 4(March (2)):156-167.
14. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10(September (5)):780-786.
15. Trotter C., Borrow R., Andrews N., Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003, 21(March (11-12)):1094-1098.
16. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994, 32(June (6)):1475-1482.
17. Holder P.K., Maslanka S.E., Pais L.B., Dykes J., Plikaytis B.D., Carlone G.M. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol 1995, 2(March (2)):132-137.
18. Makela P.H., Kayhty H., Weckstrom P., Sivonen A., Renkonen O.V. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975, 2(November (7941)):883-886.
19. Peltola H., Makela H., Kayhty H., Jousimies H., Herva E., Hallstrom K., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977, 297(September (13)):686-691.
20. Zangwill K.M., Stout R.W., Carlone G.M., Pais L., Harekeh H., Mitchell S., et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994, 169(April (4)):847-852.
21. Jacobson R.M., Jackson L.A., Reisinger K., Izu A., Odrljin T., Dull P.M. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J 2012, October.
22. Auckland C., Gray S., Borrow R., Andrews N., Goldblatt D., Ramsay M., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006, 194(December (12)):1745-1752.
23. Snape M.D., Kelly D.F., Salt P., Green S., Snowden C., Diggle L., et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006, 43(December (11)):1387-1394.
24. Cohn A.C., MacNeil J.R., Clark T.A., Ortega-Sanchez I.R., Briere E.Z., Meissner H.C., et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013, 62(March (RR-2)):1-28.